Current Immunotherapeutic Approaches for Malignant Gliomas

Glioblastoma is the most common malignant central nervous system (CNS) tumor (48.3%), with a median survival of only about 14.6 months. Although the CNS is an immune-privileged site, activated T cells can cross the blood-brain barrier. The recent successes of several immunotherapies for various canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Myung-Hoon, Kim, Choong Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819466/
https://www.ncbi.nlm.nih.gov/pubmed/35118842
http://dx.doi.org/10.14791/btrt.2022.10.e25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819466/
https://www.ncbi.nlm.nih.gov/pubmed/35118842
http://dx.doi.org/10.14791/btrt.2022.10.e25

Ejemplares similares